Tag: Genetic Counselling

Medical illustration showing spinal muscular atrophy SMA genetic screening and testing options for expectant parents

What is SMA and Why is it Trending Right Now?

Written by LPC Editorial Team on 3. March 2026. Posted in Blog, Genetics, Prenatal Care.

What is SMA and Why is it Trending Right Now?

Published

Understanding Spinal Muscular Atrophy

Spinal muscular atrophy is a genetic neuromuscular disorder that causes certain muscles to become weak and waste away. This condition affects the motor neurones in the spinal cord, which are responsible for controlling voluntary muscle movement. When these nerve cells deteriorate, muscles cannot receive the signals they need to function properly, leading to progressive weakness and atrophy.

SMA is caused by mutations in the SMN1 gene, which produces a protein essential for motor neurone survival. Without sufficient levels of this protein, motor neurones gradually die, resulting in muscle weakness that typically affects the muscles closest to the centre of the body first, including those controlling breathing, swallowing, and movement.

The condition follows an autosomal recessive inheritance pattern, meaning both parents must carry a faulty copy of the gene for their child to develop SMA. Our comprehensive spinal muscular atrophy information provides detailed guidance for families considering genetic screening.

The Five Types of SMA

SMA is classified into five distinct types based on the age of onset and severity of symptoms. Understanding these classifications helps healthcare professionals and families plan appropriate care and set realistic expectations.

SMA Type 0: The most severe form, with symptoms appearing before birth. Babies are born with severe muscle weakness and breathing difficulties.
SMA Type 1 (Werdnig-Hoffmann disease): Symptoms appear within the first six months of life. Children typically cannot sit without support and face significant breathing and feeding challenges.
SMA Type 2: Onset occurs between 6-18 months. Children can sit independently but cannot walk unassisted. Most maintain this ability throughout childhood.
SMA Type 3 (Kugelberg-Welander disease): Symptoms begin after 18 months of age. Children can walk independently initially but may lose this ability over time.
SMA Type 4: Adult-onset form with mild symptoms that typically don’t affect life expectancy significantly.

The NHS recognises that early diagnosis is crucial, as new treatments are most effective when started as soon as possible after birth.

Why SMA is Trending in Medical Circles

Several factors have brought SMA to the forefront of medical and public attention in recent years. The development of groundbreaking treatments has transformed what was once considered an untreatable condition into one where early intervention can dramatically improve outcomes.

The introduction of gene therapies and other disease-modifying treatments on the NHS has created renewed hope for families affected by SMA. These treatments work best when administered early, making prenatal and newborn screening increasingly important. The success stories emerging from early treatment programmes have captured media attention and raised public awareness.

Additionally, advances in genetic screening technology have made it easier and more accessible for couples to understand their carrier status. Advanced prenatal screening can now detect SMA risk with greater accuracy than ever before, leading to increased uptake of testing services.

High-profile campaigns by patient advocacy groups and increased research funding have also contributed to SMA’s visibility. The condition has gained attention from celebrities and public figures, further raising awareness about this previously little-known genetic disorder.

Carrier Screening and Inheritance Patterns

Approximately one in 40-50 people in the UK carries a faulty copy of the SMN1 gene, making SMA carrier screening particularly relevant for prospective parents. When both parents are carriers, there is a 25% chance with each pregnancy that their child will have SMA, a 50% chance the child will be a carrier, and a 25% chance the child will be unaffected.

Carrier screening can be performed before conception or during early pregnancy. The test involves a simple blood sample that analyses DNA for mutations in the SMN1 gene. Most carriers have no symptoms and are unaware of their status until testing reveals it.

If both partners are identified as carriers, genetic counselling becomes essential. Our genetic counselling services help couples understand their options, which may include prenatal diagnostic testing, preimplantation genetic testing (PGT), or accepting the natural risk.

The Human Fertilisation and Embryology Authority (HFEA) has approved the use of PGT-M for couples at risk of having a child with SMA Types 1, 2, or 3, providing options for family planning before pregnancy occurs.

Symptoms and Early Warning Signs

Recognising the early signs of SMA is crucial for timely intervention. Symptoms vary depending on the type of SMA, but certain warning signs should prompt immediate medical attention.

Muscle weakness: Progressive weakness that typically affects muscles closest to the torso first, including shoulders, hips, and back.
Delayed motor milestones: Late achievement of sitting, standing, or walking compared to typical developmental timelines.
Breathing difficulties: Weak respiratory muscles can cause breathing problems, particularly during sleep or illness.
Feeding challenges: Difficulty sucking, swallowing, or maintaining adequate nutrition due to weak facial and throat muscles.
Tremor: Fine trembling of fingers and hands, particularly noticeable when arms are extended.
Reduced fetal movement: In severe cases, decreased movement may be noticed during pregnancy.

Parents who notice these symptoms should seek immediate medical evaluation. Early diagnosis allows for prompt treatment initiation, which can significantly improve outcomes and quality of life.

Diagnostic Methods and Testing

Diagnosing SMA involves several approaches, depending on when the condition is suspected. Prenatal diagnosis is possible when both parents are known carriers, whilst postnatal diagnosis typically follows clinical suspicion based on symptoms.

Genetic testing remains the gold standard for SMA diagnosis. A blood sample can reveal deletions or mutations in the SMN1 gene that cause the condition. This testing can be performed prenatally through chorionic villus sampling (CVS) or amniocentesis if both parents are carriers.

Additional diagnostic tools may include electromyography (EMG) to assess muscle and nerve function, muscle biopsy in certain cases, and creatine kinase blood tests. However, genetic testing has largely replaced these more invasive procedures.

The UK National Screening Committee continues to evaluate the potential for newborn screening for SMA, recognising that early detection could improve treatment outcomes. Some regions have begun pilot programmes to assess the feasibility and benefits of population-wide newborn screening.

Treatment Breakthroughs and NHS Availability

The treatment landscape for SMA has been revolutionised in recent years, transforming the outlook for affected children and their families. Three main disease-modifying treatments are now available through the NHS, each working through different mechanisms to address the underlying genetic cause.

Spinraza (nusinersen) was the first approved treatment, administered through spinal injections every four months. This antisense oligonucleotide helps increase production of functional SMN protein from the backup SMN2 gene.

Zolgensma represents a breakthrough in gene therapy, providing a functional copy of the SMN1 gene through a single intravenous infusion. This treatment is most effective when given to babies before symptoms develop or in very early stages of the disease.

Evrysdi (risdiplam) offers an oral treatment option, taken daily as a liquid medicine. This small molecule drug increases SMN protein production and can be used across all SMA types and ages.

The NHS has made these treatments available following NICE approval, recognising their potential to dramatically improve outcomes when started early. Success stories include children who have achieved motor milestones previously thought impossible for their SMA type.

Impact on Family Planning Decisions

The availability of effective treatments has significantly influenced how families approach SMA risk in pregnancy planning. Where previously a positive diagnosis might have led to difficult pregnancy decisions, many families now feel more confident proceeding with pregnancies when SMA is detected.

However, the importance of early detection has never been greater. The most effective outcomes occur when treatment begins before symptoms develop, making prenatal diagnosis and immediate postnatal intervention crucial.

Families with a known risk of SMA have several options to consider. Prepregnancy genetic testing can identify carrier status before conception, allowing couples to make informed decisions about their reproductive choices.

For families who choose to proceed with a pregnancy at risk for SMA, comprehensive prenatal care and planning for immediate postnatal intervention becomes essential. This includes coordination with specialist neuromuscular centres and preparation for early treatment initiation if needed.

The Role of Genetic Counselling

Genetic counselling plays a vital role in helping families navigate SMA-related decisions. Professional genetic counsellors provide essential support in understanding inheritance patterns, risk assessment, and available options for testing and family planning.

During counselling sessions, families learn about the implications of carrier status, the likelihood of having an affected child, and the various testing options available. Counsellors also provide emotional support and help families process complex medical information.

For families with an SMA diagnosis, genetic counselling extends to discussing treatment options, coordinating care with specialist centres, and planning for future pregnancies. The recurrence risk remains 25% for subsequent pregnancies, making ongoing genetic counselling valuable.

Our genetic testing and counselling services provide comprehensive support throughout this process, ensuring families have access to accurate information and emotional support when making these important decisions.

Latest Research and Future Developments

Research into SMA continues to advance rapidly, with several promising developments on the horizon. Scientists are investigating combination therapies that might provide even greater benefits than current single treatments.

Studies are exploring the potential for prenatal treatment, where therapy could begin before birth to prevent symptom development entirely. Early research suggests this approach might offer the best possible outcomes for the most severe forms of SMA.

Improved screening methods are also under development, including more comprehensive carrier screening panels and enhanced newborn screening protocols. These advances could identify more at-risk pregnancies and affected newborns, enabling earlier intervention.

Long-term outcome studies are providing valuable data about the effectiveness of current treatments, helping clinicians optimise treatment protocols and timing. This research is particularly important for understanding how early intervention affects long-term development and quality of life.

How the London Pregnancy Clinic Can Help

The London Pregnancy Clinic offers comprehensive genetic screening and counselling services to support families concerned about SMA and other genetic conditions. Our experienced team provides expert guidance throughout the screening and diagnostic process.

We offer advanced carrier screening tests that can identify SMA carrier status in prospective parents. Our clinical genetics consultations provide detailed risk assessment and counselling for couples considering their family planning options.

For pregnancies identified as being at risk for SMA, we provide specialised prenatal diagnostic services and coordinate care with leading fetal medicine specialists. Our genetic counselling sessions ensure families receive comprehensive support and information to make informed decisions.

We also offer advanced prenatal screening through NIPT and other genetic testing options, helping identify pregnancies that may benefit from further diagnostic testing. Our state-of-the-art facilities and expert sonographers provide detailed ultrasound assessments when indicated.

Final Thoughts

Spinal muscular atrophy represents both a significant challenge and a remarkable success story in modern genetics and medicine. The transformation from an untreatable condition to one where early intervention can dramatically improve outcomes demonstrates the power of scientific advancement and dedicated research.

For prospective parents, understanding SMA and carrier screening options has never been more important. The availability of effective treatments means that early detection and intervention can make a profound difference in a child’s development and quality of life.

If you’re concerned about genetic conditions like SMA or considering carrier screening, our expert team is here to provide guidance and support. Contact the London Pregnancy Clinic to discuss your options and ensure you have access to the latest screening technologies and genetic counselling services.

Sources

Latest Stories

Basic vs Extended NIPT

Written by London Pregnancy Clinic on 15. January 2025. Posted in Blog, early pregnancy scan, NIPT, NIPT, Obstetrics, SMART TEST, Ultrasound. No Comments on Basic vs Extended NIPT

Choosing the Best NIPT Clinic in London: A Comprehensive Guide for Expectant Parents

Published

What is Basic NIPT?

Basic NIPT focuses primarily on detecting common chromosomal aneuploidies. These include:

Trisomy 21 (Down syndrome): The most frequently occurring aneuploidy, characterised by an extra copy of chromosome 21. This condition is associated with a spectrum of developmental delays, intellectual disabilities, and physical features such as hypotonia, a flat facial profile, and a single palmar crease.
Trisomy 18 (Edwards syndrome): Associated with severe developmental delays and physical abnormalities.
Trisomy 13 (Patau syndrome): A rare but severe condition linked to profound developmental issues.
Many basic NIPTs include sex chromosome aneuploidies, conditions that affect the number of X or Y chromosomes, such as Turner syndrome (45,X) and Klinefelter syndrome (47,XXY).

Basic NIPT typically provides results with high sensitivity and specificity for these conditions. Among the conditions tested, NIPT has the highest sensitivity and specificity for trisomy 21, and its diagnostic performance is lower for trisomy 18 and trisomy 13. However, sex chromosome aneuploidies are known to have a relatively low positive predictive value (PPV), which means they may result in a high false positive rate.

What is Extended NIPT?

Extended NIPT goes beyond the common aneuploidies to screen for additional genetic conditions. This comprehensive approach includes three distinct levels of genetic screening:

Aneuploidies

As with basic NIPT, extended screening includes common trisomies (Down, Edwards, and Patau syndromes) and sex chromosome aneuploidies, but it also assesses rarer autosomal aneuploidies affecting other chromosomes. Importantly, checking for additional syndromes does not compromise the performance of the test for trisomy 21 (Down syndrome).

Microdeletions

Microdeletions are variants of structural chromosomal anomalies. They involve the loss of small but critical segments of DNA within a chromosome. These missing segments can contain multiple important genes, leading to severe and sometimes life-altering conditions. Some microdeletions are more severe than Down syndrome (trisomy 21). Examples of microdeletion syndromes are:

22q11.2 deletion syndrome (DiGeorge syndrome): Associated with heart defects, immune dysfunction, and developmental delays.
Cri-du-chat syndrome: Caused by a deletion on chromosome 5, leading to intellectual disability and distinctive physical features.
Prader-Willi and Angelman syndromes: Resulting from deletions on chromosome 15, with unique clinical presentations.

Single-Gene Disorders (monogenic syndromes)

Most genetic syndromes in children are related to monogenic (single-gene) disorders. These tests screen for mutations in individual genes that may cause de novo or hereditary conditions. Many of these single-gene disorders can be associated with physical and/or intellectual disabilities. Examples include:

Achondroplasia: A de novo mutation resulting in a common form of dwarfism.
Apert syndrome: A genetic condition characterised by craniosynostosis (premature fusion of skull bones), distinctive facial features, and fusion of fingers, often leading to functional and aesthetic challenges.
Noonan syndrome: A condition with features like heart defects, developmental delays, and distinct facial characteristics.
Cystic fibrosis: A hereditary condition affecting the respiratory and digestive systems.

Benefits of Extended NIPT

Extended NIPT provides a more detailed assessment of the fetus’s genetic health. It is particularly advantageous in the following scenarios:

High-risk pregnancies: For parents with a family history of genetic conditions, prior pregnancies affected by genetic disorders, advanced maternal and/or paternal age, or IVF pregnancies, extended screening can offer invaluable insights.
Unexplained ultrasound findings: When ultrasound findings or abnormalities suggest a potential genetic condition, extended NIPT can help clarify the diagnosis.
In cases of increased nuchal translucency (high NT), when parents prefer to avoid invasive diagnostic tests such as CVS or amniocentesis and opt for NIPT, it is essential to consider the limitations of basic NIPT. Basic NIPT does not screen for many genetic syndromes associated with increased NT. In such situations, extended NIPT can be a preferred option, as it includes screening for monogenic conditions like Noonan syndrome, Kabuki syndrome, severe skeletal dysplasias, and other syndromes, as well as microdeletions such as 22q11.2 deletion syndrome (DiGeorge syndrome).
An additional test after normal CVS or amniocentesis results for common trisomies (Down, Edwards, and Patau syndromes) and microdeletions/microduplications is often recommended. Unfortunately, for many parents, the standard invasive diagnostic test does not check for most genetic syndromes. To check for monogenic syndromes (single gene disorders), someone needs to have a test called exome or whole genome sequencing (WGS). Extended NIPT, looking for selected monogenic syndromes, will have an additional value in those cases. It cannot replace the exome but will screen for common and serious monogenic conditions.
Reproductive planning: Knowledge of single-gene disorders or microdeletions can inform reproductive decisions, such as choosing between continuing or terminating a pregnancy, planning for specialised care or interventions post-birth, and understanding the likelihood of recurrence in future pregnancies. This information also helps families prepare emotionally and financially for potential medical needs after birth.

Choosing Between Basic and Extended NIPT

While extended NIPT offers a broader scope of screening, it also comes with additional considerations:

Cost: Extended NIPT is typically more expensive than basic NIPT, which may influence accessibility.
Time-Consuming: Because of the complexity of the tests, some of the extended NIPTs can have much longer turnaround time.
False Positives: Screening for microdeletions and sex chromosome aneuploidies may yield higher rates of false positives compared to basic NIPT, necessitating confirmatory diagnostic tests such as amniocentesis or chorionic villus sampling (CVS). Among the various conditions tested, extended NIPT shows the poorest performance for these two categories due to different biological and technical challenges.
False-Negatives: All NIPTs are screening tests and can have false-negative results due to technological limitations and biological reasons. Many genetic conditions are associated with multiple genes, and these tests are designed to detect only known and relatively common pathogenic mutations, leaving rarer or unknown variants undetected.
There is a small possibility of identifying a pathogenic single-gene variant (mutation) inherited from a parent. For example, a parent may carry a mild or subclinical form of a genetic disorder without being aware of it. Thorough genetic counselling is essential in such cases to evaluate the potential impact of this variant on the unborn child and to provide tailored advice for the family.
Counselling Needs: The complexity of results from extended NIPT often requires detailed genetic counselling to help families understand the findings and their implications.
Only highly advanced genomic laboratories can develop extended NIPT tests capable of detecting monogenic conditions and microdeletions. While these branded extended NIPTs are extensively evaluated and validated internally, they still lack independent validation. It is essential to mention that even basic NIPTs, such as the widely used TDL NIPT in London, have not been validated by external organisations, leaving the actual performance of these tests uncertain.

Genetic Labs and Their Brands of Extended NIPT

Fulgent Genetics (US), an accredited leader in clinical diagnostic genetic sequencing, provides the KNOVA test, which screens for a wide range of single-gene disorders and chromosomal anomalies. KNOVA features a meticulously curated panel of de novo genetic conditions designed to optimise diagnostic performance while minimising false-positive rates. Currently, KNOVA is regarded as one of the best choices for extended NIPT panels in the UK. At London Pregnancy Clinic we offer it as part of out state-of-the-art SMART Test NIPT screening method.

Natera’s (US) Panorama test, which includes screening for microdeletions, and the separate Vistara test, focuses on single-gene disorders. Natera was a pioneer in the development of extended NIPT; however, other companies now offer more comprehensive screening panels. Notably, the Panorama test for 22q11.2 deletion syndrome is the only extended NIPT validated by an independent study, demonstrating a detection rate of approximately 80% and a positive predictive value of about 50%.

Eurofins Genoma (Italy) offers the PrenatalSafe Complete Plus test, which screens for all aneuploidies, microdeletions, and selected monogenic disorders. A unique feature of this test is its ability to screen for cystic fibrosis and its applicability in cases of vanishing twin syndrome. However, PrenatalSafe Complete Plus has a limited monogenic disorders panel, a very long turnaround time, and is relatively expensive.

BGI Genomics (China) features the NIFTY Mono test, specialising in detecting monogenic conditions and other genetic anomalies. Nifty Mono offers probably the most comprehensive panel, screening for hundreds of chromosomal and genetic disorders. However, there are significant concerns regarding the use of patient data by BGI. In 2023, a group of MPs and peers in the UK submitted a letter to the Information Commissioner’s Office, requesting an investigation into privacy concerns surrounding BGI Group, particularly its NIFTY prenatal tests.

BillionToOne (US) offers the UNITY test, which uniquely combines carrier screening with fetal screening. UNITY screens for inherited single-gene disorders such as cystic fibrosis, sickle cell anaemia, and thalassemias, providing detailed insights into both parental and fetal genetic health. Notably, the UNITY and KNOVA panels are complementary, enabling enhanced diagnostic performance when used together.

Final Thoughts.

Choosing between basic and extended NIPT depends on individual circumstances, risk factors, and the level of detail desired in genetic screening. While basic NIPT provides robust detection of common aneuploidies, extended NIPT offers a deeper dive into genetic health by screening for microdeletions and single-gene disorders. It is anticipated that future developments in extended NIPT panels will increasingly focus on screening for monogenic (single-gene) disorders, given their clinical significance and the growing demand for more comprehensive prenatal testing options. Consulting with healthcare professionals and genetic counsellors can help families navigate these choices and ensure the best possible care for both the expectant mother and her baby.

When choosing a clinic for your NIPT, ensure they use advanced high-resolution ultrasound technology for the pre-test scan. High-quality imaging allows for a more accurate assessment of fetal health, which is crucial, particularly in the early stages of pregnancy (10-11 weeks). Avoid clinics with outdated or low-resolution scanners, as this can compromise the accuracy of the scan and potentially impact the performance of your NIPT.

Latest Stories

Genetic Counselling Services Launch

Written by London Pregnancy Clinic on 12. June 2024. Posted in Blog, Genetics, NIPT, SMART TEST, Women's health. No Comments on Genetic Counselling Services Launch

Genetic Counselling Services Launch

Discover the importance of Genetic Counselling before and during pregnancy.

Published
Last Modified

Genetic Testing We offer

At London Pregnancy Clinic, we offer a range of advanced genetic tests. These tests provide crucial information about your reproductive health. Here are the key tests we provide:

SMART Test: Our SMART Test NIPT is the most advanced non-invasive prenatal test and scan package in the world. This signature test gives parents detailed knowledge about their baby’s health without the risks of invasive testing. We offer two genetic packages: SMART Test KNOVA, performed by the leading US lab Fulgent, and SMART Test Genoma, performed by the top European lab Eurofins. Genetic counselling before the SMART test is essential to understand its advantages and limitations, ensuring you make an informed decision about your baby’s health.

Basic NIPT: The Basic NIPT is another non-invasive prenatal test we offer. It focuses on detecting the most common chromosomal abnormalities, including Down syndrome. Like the NIPT Smart Test, it uses a simple blood draw from the mother. This test is an excellent option for those seeking essential genetic information. With its high accuracy, it ensures peace of mind during pregnancy.

Carrier Screening: Our comprehensive carrier screenings identify if you or your partner are carriers of specific genetic disorders. This test covers a wide range of conditions, including cystic fibrosis and spinal muscular atrophy. Knowing your carrier status helps in planning for a healthy pregnancy. It allows you to explore reproductive options like IVF with preimplantation genetic testing (PGT). Moreover, carrier screening informs family members about potential genetic risks.

It’s important to distinguish between Non-Invasive Prenatal Testing (NIPT) and carrier screening:

NIPT: Performed during pregnancy, typically between 10-20 weeks. It screens the fetus’s DNA for chromosomal abnormalities like Down syndrome.
Carrier Screening: Tests the parents’ DNA for specific gene mutations that could be passed to their child. It can be done before or during pregnancy.

Benefits of Genetic Testing

Genetic testing offers several advantages, not just for you but for your entire family. Here are some key benefits:

Understanding Health Risks: Genetic testing identifies if you or your partner carry genes for specific genetic conditions. This understanding helps assess the risk of passing these conditions to your children.

Informed Decisions: Knowing your genetic risks allows you to make informed choices about pregnancy and family planning. You can consider options like IVF with preimplantation genetic testing (PGT-M), early interventions, or other preventive measures.

Personalised Care: With detailed genetic information, doctors can provide more personalised care. They can recommend specific tests, treatments, or lifestyle changes to help manage or reduce health risks.

Family Health Insights: Genetic testing reveals crucial health information that may affect other family members. If a genetic condition is identified, relatives can also get tested and take steps to manage their health.

Early Intervention: Detecting genetic conditions early leads to timely interventions and better management. This approach improves the quality of life for affected individuals.

Peace of Mind: For many, genetic testing provides peace of mind. Knowing your genetic information can alleviate uncertainties about potential health risks.

Preventive Measures: Genetic testing enables preventive measures, potentially reducing the risk of having a child with a genetic syndrome.

Overall, genetic testing empowers you with knowledge about your health and your family’s health. It helps you make well-informed decisions and take proactive steps. This ensures the best possible outcomes for you and your loved ones.

Impact on Family Planning?

Our carrier screening tests identify carriers of specific genetic disorders. Even without symptoms, you might still be a carrier. This knowledge is crucial for informed family planning. Knowing your carrier status can significantly influence family planning decisions. Couples who are both carriers face a 25% risk of having an affected child. This information empowers them to explore various reproductive options, such as:

Using donor gametes to conceive.
Pursuing in vitro fertilisation (IVF) with preimplantation genetic testing (PGT).
Accepting the risk and preparing for a potentially affected child.
Considering adoption or remaining childless.

Carrier results can also influence the timing of pregnancy, prenatal testing decisions, early intervention for certain conditions, and emotional preparedness. Carrier screening identifies carriers for many genetic conditions, including:

Cystic Fibrosis
Spinal Muscular Atrophy (SMA)
Sickle Cell Disease
Tay-Sachs Disease
Fragile X Syndrome
Duchenne Muscular Dystrophy

Other conditions include Thalassemias (alpha and beta), Familial Dysautonomia, Fanconi Anemia, Gaucher Disease, and Niemann-Pick Disease.

Importance of Genetic counselling

Genetic counselling is vital in the carrier screening process. Our certified clinical genetic counsellors are dedicated to supporting you through every step. Here’s how:

Educating the Public and Healthcare Professionals: We provide standardised education about genetic carrier screening. This knowledge empowers you and your healthcare providers with essential information.

Pre-Test Counselling: Before testing, we outline the screening process and potential outcomes. This preparation ensures you are fully informed and ready.

Post-Test Counselling: After testing, we interpret your results and discuss your options. This support helps you understand your situation and make informed decisions about your reproductive health.

Collaborating with Healthcare Providers: Our counsellors work with other healthcare providers to ensure comprehensive care in complex cases. This collaboration enhances your overall care experience.

In summary, London Pregnancy Clinic’s genetic testing and genetic counselling services offer comprehensive support and essential information. These services empower you to make informed decisions and take proactive steps for your family’s health. For more information or to schedule a test, please visit our website or contact us directly. Our team is here to support you in planning a healthy future for your family.

Ethical and Emotional Support:

Genetic counselling provides ethical guidance and emotional support. Our genetic counsellors help individuals and families navigate complex genetic information. Here’s how we assist:

Risk Assessment: We evaluate your risk based on family history, ethnic background, and genetic test results. This assessment is crucial for understanding potential health risks.
Informed Decision-Making: Knowing your genetic risks allows you to make informed choices about genetic testing and reproductive options. This empowers you to take control of your health and family planning.
Explaining Test Results: We interpret your genetic test results and explain their implications. This helps you understand what the results mean for you and your family.
Emotional Support: We offer emotional support and coping strategies. Understanding genetic risks can be challenging, and our counsellors are here to help you navigate these emotions.
Personalised Healthcare Recommendations: Based on your genetic profile, we provide personalised healthcare recommendations. This ensures you receive care tailored to your specific needs.

We are excited to welcome Ms Ailidh Watson to our team as our genetic counselling specialist. Ailidh is a registered private genetic counsellor with a broad range of experience. She has specialist interests in prenatal care and patients with cleft lip and/or palate. Her qualifications include a BSc (Hons) in Genetics from the University of Glasgow and an MSc in Genomic Counselling from the University of Manchester, where she graduated with distinction.

Ailidh’s credentials also include the Skilled Helper Course and registrations with AHCS and HCPC. Her services at LPC include genetic counselling, carrier screening, NIPT counselling, and prenatal screening, including NIPT. Ailidh will be your go-to person for all things genetic counselling.

Final Thoughts

London Pregnancy Clinic’s genetic counselling services represent a comprehensive approach to reproductive health. These services combine advanced genetic testing with expert counselling tailored to individual needs. They empower couples with the knowledge to make informed reproductive choices aligned with their values and circumstances.